qiaoruosu

Qiaoruosu (also referred to as Qiaoruisu) is a Chinese patent medicine (CPM) developed and manufactured by Hubei Furen Pharmaceutical. It is primarily indicated for the treatment of respiratory conditions, including cough and asthma associated with 'phlegm-heat syndrome,' as well as acute exacerbations of chronic bronchitis. The formulation is designed to clear heat, resolve phlegm, and suppress cough and wheezing. As a marketed product in China, it is currently undergoing a Phase IV post-marketing safety and efficacy study (CTR20250703) to evaluate its performance in real-world clinical settings. The drug is typically administered orally in capsule form.

Brand names

QiaoruosuQiaoruisu翘蕊苏

Other names

Qiaoruisu capsule翘蕊苏胶囊Qiaoruisu